Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.46 |
| ▸ | DRD4 known ✓ | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.46 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.43 |
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.42 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29848871 | 1.00 | DRD2 (0.46) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL2859604 | 0.99 | DRD2 (0.47) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18394841 | 0.94 | DRD2 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL28638282 | 0.82 | OPRL1 (0.54) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL18395601 | 0.81 | DRD3 (0.47) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL17364174 | 0.81 | OPRM1 (0.49) | DRD2DRD4DRD3DRD1OPRL1 | |
| SCHEMBL18408637 | 0.80 | DRD3 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL31280938 | 0.80 | KMT2A (0.47) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL24489451 | 0.78 | OPRL1 (0.65) | DRD2OPRL1SIGMAR1POLBOPRM1 | |
| SCHEMBL17411365 | 0.78 | OPRM1 (0.45) | OPRL1SIGMAR1OPRM1OPRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | claimed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | claimed |
| EP-4049998-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd. (IL) | 2022-08-31 | — | — | EP | disclosed |
| EP-3160470-B1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Prilenia Neurotherapeutics Ltd (IL) | 2022-08-03 | — | — | EP | disclosed |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2022-01-27 | — | — | US | disclosed |
| CN-113511997-A | Pridopidine analogues, their preparation and use | 普丽莱尼亚神经治疗有限公司 | 2021-10-19 | — | — | CN | disclosed |
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2021-10-12 | — | — | US | disclosed |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PRILENIA NEUROTHERAPEUTICS LTD. | 2020-01-30 | — | — | US | disclosed |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2019-09-10 | — | — | US | disclosed |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2019-01-31 | — | — | US | disclosed |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2018-11-20 | — | — | US | disclosed |
| EP-3160470-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | Teva Pharmaceutical Industries Ltd (IL) | 2017-05-03 | — | — | EP | disclosed |
| CN-106456618-A | Pridopidine analogues, their preparation and use | 泰华制药工业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016003919-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-07 | — | — | WO | disclosed |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141412-B2 | Analogs of pridopidine, their preparation and use | PDE7A, PDE3A, PDE4D | DRD2 7/4885DRD4 14/4885DRD3 21/4885 |
| US-10406145-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20200030308-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20220023280-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | PDE3A, PDE4D, PDE9A | DRD2 14/4885DRD4 29/4885DRD3 30/4885 |
| US-20190030016-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 4/4885DRD3 5/4885 |
| US-20150374677-A1 | ANALOGS OF PRIDOPIDINE, THEIR PREPARATION AND USE | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 7/4885DRD3 5/4885 |
| US-10130621-B2 | Analogs of pridopidine, their preparation and use | QDPR, DRD2, OPRD1 | DRD2 2/4885DRD4 7/4885DRD3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.